Nov 16, 2021 / 10:40AM GMT
Peter James Welford - Jefferies LLC, Research Division - Senior Equity Analyst & European Pharmaceuticals Analyst
(technical difficulty) Jefferies in London. It's my great pleasure to introduce the next company in this track, which is QIAGEN. And it's our great pleasure to have here to chat with us today in fact, Roland Sackers, the CFO. And I think we've also got Phoebe and John here in the audience as well from Investor Relations.
With that, Roland is going to make a few introductory remarks, and then we'll get into Q&A. So thank you very much for your time, Roland, and thank you all for attending. Thank you.
Roland Sackers - QIAGEN N.V. - CFO, MD & Member of Management Board
Yes. Again, thanks, Peter, and thanks Jefferies for having us. First physical meeting after a long time, so I'm glad to be here. Still somewhat not used to see so many faces without masks. So again, it's clearly something we'll, particularly Germany, have to get used to.
Nevertheless, going back to QIAGEN, clearly quite a ride over the overall COVID period.
Qiagen NV at Jefferies London Healthcare Conference (Virtual) Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers